TNFSF13B and systemic lupus erythematosus: As suggested by the post-hoc analyses of the Belimumab trials (BLISS-52 and BLISS-76) (Zhao et al., 2007; Burkly, 2014), baseline BAFF levels were proposed to be potentially useful in identifying SLE patients in which Belimumab might be expected to be more successful (Roth et al., 2016).